OneMedNet Secures AI Drug Developer for iRWD Platform; Scale and Liquidity Concerns Persist

What happened

OneMedNet announced a new agreement to supply de-identified, full-fidelity clinical real-world data to a leading AI-driven drug development company. The iRWD platform enabled cohort feasibility in minutes, data validation within a week, and a signed contract within three weeks of initial contact. This showcases the platform's efficiency and potential appeal in the high-growth AI drug discovery market. However, the company's financial position remains precarious, with sub-scale revenue ($155K in Q2 2025) and acute liquidity constraints ($0.1M cash, $1.6M Bitcoin as of June 30, 2025). The deal aligns with the strategic pivot to iRWD after decommissioning BEAM, but it is a single contract and does not yet resolve going-concern doubts or Nasdaq compliance risks.

Implication

The deal demonstrates that the iRWD platform can attract customers in the AI drug development space, a high-growth area with increasing demand for curated imaging data. However, OneMedNet's revenue base remains tiny, and one contract is unlikely to materially change near-term financials or resolve the going-concern flag. Investors should monitor whether this leads to repeat business or larger contracts and whether the company can scale iRWD revenue to the $1M+ quarterly level that would indicate traction. Liquidity and Nasdaq compliance remain critical risks, and until those are addressed, the stock remains high risk. The rapid sales cycle highlighted in the release is encouraging, but sustained demand needs further evidence.

Thesis delta

The news provides initial validation of the iRWD product in the AI drug development market, which was a watch item for moving from SELL to HOLD. However, the master report's SELL stance was based on severe liquidity and scale concerns, and this single contract does not yet address those. The thesis delta is that the probability of iRWD traction increases slightly, but the overall stance remains SELL until consistent revenue growth and balance sheet improvement are demonstrated.